Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Receivables - Accured (2018 - 2020)

Marker Therapeutics (MRKR) has disclosed Revenue - Other for 1 consecutive years, with $1828.0 as the latest value for Q2 2016.

  • Quarterly Revenue - Other changed N/A to $1828.0 in Q2 2016 from the year-ago period, while the trailing twelve-month figure was $1828.0 through Jun 2017, changed N/A year-over-year, with the annual reading at $1828.0 for FY2016, N/A changed from the prior year.
  • Revenue - Other for Q2 2016 was $1828.0 at Marker Therapeutics.
  • The five-year high for Receivables - Accured was $112200.0 in Q1 2019, with the low at $135.0 in Q3 2020.
  • Average Receivables - Accured over 3 years is $53511.6, with a median of $56189.0 recorded in 2019.
  • The sharpest move saw Receivables - Accured crashed 48.06% in 2019, then crashed 99.83% in 2020.
  • Over 3 years, Receivables - Accured stood at $108177.0 in 2018, then plummeted by 48.06% to $56189.0 in 2019, then tumbled by 99.01% to $559.0 in 2020.
  • According to Business Quant data, Receivables - Accured over the past three periods came in at $559.0, $135.0, and $3440.0 for Q4 2020, Q3 2020, and Q2 2020 respectively.